Mounjaro®
Starting from £179.99/mo
Start journey Learn moreSemaglutide does not show up on standard military drug tests. Military drug screening panels target substances with abuse potential — controlled drugs, narcotics, stimulants — and semaglutide is none of those. It is a GLP-1 receptor agonist prescribed for weight management and type 2 diabetes, with no psychoactive properties and no inclusion on any standard military toxicology panel. That said, anyone in service using a prescription medicine should understand exactly how that medicine is classified, what panels test for, and what their chain of command or medical officer may require to know. This page works through each of those questions in turn, drawing on NHS guidance on semaglutide and the regulatory record. Because semaglutide is a prescription-only medicine, a clinician must assess your suitability before any treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Military drug testing (whether in the UK armed forces or NATO-aligned services) follows a toxicology framework designed to detect substances that impair judgment, create dependency, or are controlled under law. The standard panel covers drugs like cannabis metabolites, opioids, cocaine, amphetamines, MDMA, and benzodiazepines. Some panels add anabolic steroids, particularly in fitness-intensive roles.
Semaglutide is not screened for on any of these panels. It is a synthetic peptide, a large molecule that mimics the action of a gut hormone called GLP-1. It works by signalling fullness, slowing gastric emptying, and moderating blood-sugar response. None of that mechanism resembles a controlled substance, and no regulatory body classifies it as one. If you want the technical detail on how the medicine functions, the semaglutide overview on our site covers the pharmacology clearly.
To be direct: a standard urine or blood drug screen will not detect semaglutide, because no panel is designed to look for it. If you are wondering whether semaglutide can show up on a drug test at all, the short answer is that standard panels have no mechanism to identify it. For context on what blood-based testing can and cannot show, see our page on semaglutide in blood tests.
A reasonable follow-up concern is cross-reactivity, could semaglutide cause a false positive for something else on the panel? The answer, based on the pharmacological profile, is no. Cross-reactivity in immunoassay-based drug tests occurs when a molecule shares structural similarities with a target drug. Semaglutide is a large peptide with a molecular structure entirely distinct from any screened substance. It does not bind the antibodies used in standard immunoassay kits for cannabinoids, opioids or stimulants.
This is consistent with what UK prescribers understand about the medicine. The NHS medicines page for semaglutide lists known interactions, these relate to medicines whose absorption may be affected by slowed gastric emptying, particularly oral contraceptives and some antibiotics. There is no documented interaction with drug-testing reagents.
If your role requires regular or random testing, our page on whether semaglutide will show up in a drug test explains in plain terms why routine screening is not designed to detect it, which may be useful reading before you speak to your medical officer. Your prescriber can provide confirmation of the medicine, dose and clinical indication.
This is the part that matters most in practice. Military service creates specific medical disclosure obligations that civilian patients do not face. Most armed forces require personnel to notify their medical officer of any prescription medicine, particularly where that medicine could affect physical performance, alertness, or operational readiness.
Semaglutide's common side effects (nausea, fatigue, occasional dizziness, especially in the first few weeks) are worth discussing with a military doctor before you start. These are temporary for most people, and the graduated dose schedule is designed to minimise them, but a medical officer in your chain of care should be aware. For a fuller picture of what to expect, our Wegovy treatment page outlines the dose titration process and side effect profile that prescribers discuss with patients.
Disclosure is not a barrier to treatment. Many service personnel take prescription medicines for long-term conditions without any impact on their status. The key is that your military medical record reflects your full health picture. Starting a prescription treatment without informing your medical officer creates an administrative gap, not a drug-test problem, but the gap itself can cause complications.
If you are considering semaglutide for weight management and want to explore private treatment, the process at a regulated UK pharmacy starts with a clinical consultation. At nume, a GPhC-registered Independent Prescriber reads your responses the same day, a real clinician, not automated software. If treatment is appropriate, your prescription is issued and your order is dispatched the same day when placed before 12pm, arriving by DPD the next working day in plain, unbranded packaging with a tracking link on your phone.
For context on what private treatment costs and what that price includes, our guide to obtaining Wegovy through a licensed UK pharmacy is a useful starting point. Treatment pricing is shown on the treatment overview page. Semaglutide is a prescription-only medicine, clinical assessment is not optional, and a prescriber decides suitability based on your full health picture, including any medications or circumstances relevant to your situation. For general questions about weight management options, the weight management page covers the landscape.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.